Back to all journals
journal articles
LETTER TO THE EDITORE: CLARITY AD OPEN-LABEL EXTENSION DATA DO NOT ROBUSTLY CONFIRM DISEASE COURSE MODIFICATION BY LECANEMAB IN APOE4 HETEROZYGOTES AND NON-CARRIERS
Lutz Froelich
CITATION:
Lutz Froelich (2025): Letter to the editor: Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE4 heterozygotes and non-carriers. # TJPAD-D-26-00165. The Journal of Prevention of Alzheimer’s Disease (JPAD). https://doi.org/10.1016/j.tjpad.2026.100588